Sex-driven differences in immunological responses: Challenges and opportunities for the immunotherapies of the third millennium

International Reviews of Immunology

Volumn 34, Issue 2, 2015, Pages 134-142

  Mirandola, Leonardo ^a,b,c   Wade, Raymond ^a   Verma, Rashmi ^a   Pena, Camilo ^a   Hosiriluck, Nattamol ^a   Figueroa, Jose A ^a,c   Cobos, Everardo ^a,b,c   Jenkins, Marjorie R ^b   Chiriva Internati, Maurizio ^a,b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b University Health Sciences Center Amarillo   (United States)

^c Kiromic Inc   (United States)

Author keywords

Cancer vaccines; Cancer testis atigens; Hormones; Immune response

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; ESTROGEN; PROTEIN; ROPPORIN 1; TESTOSTERONE; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; ROPN1 PROTEIN, HUMAN; SEX HORMONE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; MEDICAL RESEARCH; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEX DIFFERENCE; T LYMPHOCYTE; X CHROMOSOME; Y CHROMOSOME; ANIMAL; CLINICAL TRIAL (TOPIC); FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; SEX;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION; GONADAL STEROID HORMONES; HUMANS; IMMUNITY; IMMUNOTHERAPY; MALE; MEMBRANE PROTEINS; RHO GTP-BINDING PROTEINS; SEX; SEX FACTORS;

EID: 84928549196     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2015.1018417     Document Type: Review

References (41)

1. Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 2011;35(3):565-572.
2. Marts SA, Keitt S. Foreward: A historical overview of advocacy for research in sex-based biology. Adv Mol Cell Biol 2004;34:v-xiii.
3. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009;48(3):143-157.
4. Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: Interaction with biological differences between men and women. Br J Pharmacol 2014;171(3):580-594.
5. Berger JS, Elliott L, Gallup D, et al. Sex differences inmortality following acute coronary syndromes. JAMA 2009;302(8):874-882.
6. Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J hepatol 2010;2(8):302-310.
7. Frost M, Gudex C, Rubin KH, et al. Pattern of use ofDXA scans in men: A cross-sectional, populationbased study. Osteoporos Int 2012;23(1):183-191.
8. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010;28(26):4086-4093.
9. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999;103(2 Pt 1):282-288.
10. Kanda N, Tsuchida T, Tamaki K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exp Immunol 1996;106(2):410-415.
11. Cyster JG, Goodnow CC. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 1995;2(1):13-24.
12. Dinesh RK, Hahn BH, Singh RP. PD-1, gender, and autoimmunity. Autoimmun Rev 2010;9(8):583-587.
13. Merino R, Ding L, Veis DJ, et al. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 1994;13(3):683-691.
14. Sato S, Tuscano JM, Inaoki M, Tedder TF. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 1998;10(4):287-297.
15. Sthoeger ZM, Chiorazzi N, LahitaRG. Regulation of theimmune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol 1988;141(1):91-98.
16. Nostrati A, Wei ML. Sex disparities in melanoma outcomes:The role of biology. Arch Biochem Biophys 2014;563:42-50.
17. Sthoeger ZM, ZingerH, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 femalemice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 2003;62(4):341-346.
18. Fish EN.The X-files in immunity: Sex-based differences predispose immune responses. Nat Rev Immunol 2008;8(9):737-744.
19. Amadori A, Zamarchi R, De Silvestro G, et al. Genetic control of the CD4/CD8 T-cell ratio in humans. NatMed 1995;1(12):1279-1283.
20. Arruvito L, Sanz M, Banham AH, Fainboim L. Expansion of CD4+CD25+and FOXP3 +regulatory T cells during the follicular phase of the menstrual cycle: Implications for human reproduction. J Immunol 2007;178(4):2572-2578.
21. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol 2008;9(3):239-244.
22. Lawson CA, Brown AK, Bejarano V, et al. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 2006;45(10):1210-1217.
23. Mo R, Chen J, Grolleau-Julius A, et al. Estrogen regulates CCR gene expression and function in T lymphocytes. J Immunol 2005;174(10):6023-6029.
24. Pernis AB. Estrogen and CD4+ T cells. Curr Opin Rheumatol 2007;19(5):414-420.
25. Kramer PR, Winger V, Kramer SF. 17beta-Estradiol utilizes the estrogen receptor to regulate CD16 expression in monocytes.Mol Cell Endocrinol 2007;279(1-2):16-25.
26. Kramer PR, Kramer SF, Guan G. 17 beta-estradiol regulates cytokine release through modulation of CD16 expression in monocytes and monocyte-derived macrophages. Arthritis Rheum 2004;50(6):1967-1975.
27. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005;11(4):411-423.
28. Garcia-Duran M, de Frutos T, Diaz-Recasens J, et al. Estrogen stimulates neuronal nitric oxide synthase protein expression in human neutrophils. Circ Res 1999;85(11):1020-1026.
29. Miyagi M, Aoyama H, Morishita M, Iwamoto Y. Effects of sex hormones on chemotaxis of human peripheral polymorphonuclear leukocytes and monocytes. J Periodontol 1992;63(1):28-32.
30. Hao S, Zhao J, Zhou J, et al. Modulation of 17beta-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors. Int Immunopharm 2007;7(13): 1765-75.
31. Seillet C, Rouquie N, Foulon E, et al. Estradiol promotes functional responses in inflammatory and steady-state dendritic cells through differential requirement for activation function-1 of estrogen receptor alpha. J Immunol 2013;190(11):5459-5470.
32. Carreras E, Turner S, Frank MB, et al. Estrogen receptor signaling promotes dendritic cell differentiation by increasing expression of the transcription factor IRF4. Blood 2010;115(2):238-246.
33. Siracusa MC, Overstreet MG, Housseau F, et al. 17beta-estradiol alters the activity of conventional and IFN-producing killer dendritic cells. J Immunol 2008;180(3):1423-1431.
34. Brooks EG, Schmalstieg FC, Wirt DP, et al. A novel X-linked combined immunodeficiency disease. J Clin Invest 1990;86(5):1623-1631.
35. van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol 2007;2007:89017.
36. Sundar R, Soong R, Cho BC, et al. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer (Amsterdam) 2014;85(2):101-109.
37. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384(9948):1109-1117.
38. Lin PY, Sun L, Thibodeaux SR, et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 2010;185(5):2747-2753.
39. Shigematsu Y, Hanagiri T, Shiota H, et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung cancer (Amsterdam) 2010;68(1):105-110.
40. GureAO, ChuaR, WilliamsonB, et al.Cancer-testis genes are coordinately expressed and aremarkers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11(22):8055-8062.
41. Chiriva-InternatiM, Mirandola L, Yu Y, et al. Cancer testis antigen, ropporin, is a potential target for multiplemyeloma immunotherapy. J Immunother 2011;34(6):490-499. International